Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6 ...

Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during ...

Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) has earned an average recommendation of “Hold” from the twenty-one ratings firms that are presently covering the stock, Marketbeat Ratings reports.

Dividend stocks have been extremely rewarding for long-term investors. Data shows that roughly 55% of market returns from ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...

Stocks: Real-time U.S. stock quotes reflect trades reported through ... Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%. That ...